BillionToOne vs Burning Rock Biotech
BLLN and BNR side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BLLN and BNR compare
BillionToOne grew revenue faster over the last twelve months (71.9% versus 4.6% for Burning Rock Biotech).
BillionToOne keeps more of each dollar of sales as profit, with a net margin of 11.3% compared with −10.3% at Burning Rock Biotech.
BillionToOne scores higher on the StockData Score (11 against 5 for Burning Rock Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BLLN | BNR |
|---|---|---|
| Size and price | ||
| Market cap | $5.0B | – |
| Share price | $105.15 | $13.29 |
| Change, 1 year | 3.3% | 8.8% |
| Change, 5 years | – | −92.2% |
| Beta (5Y) | −0.04 | 1.73 |
| Employees | 713 | 667 |
| StockData Score | ||
| Total score | 11 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 2 | 2 |
| Health score | 6 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 11.4× | – |
| P/B | 8.8× | – |
| EV/EBITDA | 84.8× | – |
| P/FCF | 146× | – |
| FCF yield | 0.68% | – |
| Growth | ||
| Revenue growth (TTM) | 71.9% (better) | 4.6% |
| Revenue growth, 5Y average | – | 4.6% |
| Profitability | ||
| Gross margin | 71.4% | 74.7% (better) |
| Operating margin | 10.2% (better) | −10.2% |
| Net margin | 11.3% (better) | −10.3% |
| FCF margin | 7.8% (better) | −6.2% |
| Return on equity | 30.2% (better) | −9.9% |
| Return on invested capital | – | −72.5% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 (better) |
| Interest coverage | 1655× | – |
| Current ratio | 11.25 (better) | 2.99 |
| Altman Z-score | 16.67 | – |
| Piotroski F-score | 8 (better) | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 32.4% | 1.8% |
| Held by insiders | 55.7% | 19.0% |
| Insider net buying, 12 months | −$58.5M | $11.6M (better) |
| Short interest, % of float | 14.2% | – |
Go deeper
- BLLN stock overview
- BLLN income statement
- BLLN valuation and score
- BNR stock overview
- BNR income statement
- BNR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.